Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor
Objective Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. The aim of this study was to characterize B cell immunosuppression mediated by the Fc‐engineered antibody, XmAb5871, which coengages FcγRIIb with the B cell...
Gespeichert in:
| Veröffentlicht in: | Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2014-05, Vol.66 (5), p.1153-1164 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1164 |
|---|---|
| container_issue | 5 |
| container_start_page | 1153 |
| container_title | Arthritis & rheumatology (Hoboken, N.J.) |
| container_volume | 66 |
| creator | Chu, Seung Y. Yeter, Karen Kotha, Roshan Pong, Erik Miranda, Yvonne Phung, Sheryl Chen, Hsing Lee, Sung‐Hyung Leung, Irene Bonzon, Christine Desjarlais, John R. Stohl, William Szymkowski, David E. |
| description | Objective
Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. The aim of this study was to characterize B cell immunosuppression mediated by the Fc‐engineered antibody, XmAb5871, which coengages FcγRIIb with the B cell antigen receptor (BCR) complex and that is currently in clinical development for the treatment of rheumatoid arthritis (RA). Because rheumatoid factor (RF) might interfere with the binding of XmAb5871 to FcγRIIb, we correlated RF titers with the potency of XmAb5871.
Methods
We analyzed the expression of CD19, FcγRIIb, and CD86 on naive and memory B cells from 50 patients with RA and 66 healthy donors, quantified XmAb5871‐induced promotion of FcγRIIb phosphorylation and suppression of calcium flux in activated B cells, measured CD86 inhibition in whole blood, and correlated RF and anti−citrullinated protein antibody (ACPA) levels with drug potency. We engrafted RA peripheral blood mononuclear cells (PBMCs) into SCID mice, treated them with XmAb5871, and quantified human total IgG, total IgM, and anti‐tetanus IgG antibody levels in vivo.
Results
B cells from all donors expressed CD19 and FcγRIIb, and the expression of FcγRIIb was higher on naive, but not memory, B cells from donors with RA compared with healthy donors. BCR‐mediated calcium flux was suppressed by XmAb5871 and was associated with FcγRIIb phosphorylation. XmAb5871 inhibited CD86 induction, and the levels of RF and ACPAs did not affect efficacy. XmAb5871 suppressed B cell activation regardless of disease severity. In SCID mice engrafted with PBMCs from a patient with RA, XmAb5871 suppressed humoral responses.
Conclusion
Coengagement of the BCR complex and FcγRIIb by XmAb5871 inhibits B cell activation and function. The similar potency in patients with RA and healthy donors and the absence of autoantibody interference suggest that XmAb5871 may represent a new therapeutic strategy to suppress autoreactive B cells in RA. |
| doi_str_mv | 10.1002/art.38334 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1520345810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1520345810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3254-d1aab59d0d0de1d7051b0042ae97aa7f55cbca5e7095f74795f7f309aa60f2173</originalsourceid><addsrcrecordid>eNp1kUFOwzAQRS0EAgQsuADyEiRK7SSum2UIFCpVQipFYhfZyaQ1SuJgJ4LsOALXYM09OAQnwbQUVngke-x5_tLMR-iQkjNKiNcXpjnzh74fbKBdz_cGPeYRtrnOaUh30IG1D8StkJMBYdtoxwv40KM83EVvt21dG7BW6QrrHE8X0Jai0SrDkWkWRjXK4nMcQ1FYLDt8X0aSDTk9xaLCUdWoz5fX-IKGy1zqrMOzhWhwrKGaizms_y7Lc6jwFFKoG20cUdYFPDuZDI_Sj_e_yngs8bhaKKncrft930dbuSgsHPyce-hudDmLr3uTm6txHE16qe-xoJdRISQLM-ICaMYJo5KQwBMQciF4zlgqU8GAk5DlPODfe-6TUIgByd1M_D10vNKtjX5swTZJqWzqehAV6NYm1M3XD9iQEoeerNDUaGsN5EltVClMl1CSfJuTOHOSpTmOPfqRbWUJ2S-5tsIB_RXwpAro_ldKoulsJfkFNhCaGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1520345810</pqid></control><display><type>article</type><title>Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Chu, Seung Y. ; Yeter, Karen ; Kotha, Roshan ; Pong, Erik ; Miranda, Yvonne ; Phung, Sheryl ; Chen, Hsing ; Lee, Sung‐Hyung ; Leung, Irene ; Bonzon, Christine ; Desjarlais, John R. ; Stohl, William ; Szymkowski, David E.</creator><creatorcontrib>Chu, Seung Y. ; Yeter, Karen ; Kotha, Roshan ; Pong, Erik ; Miranda, Yvonne ; Phung, Sheryl ; Chen, Hsing ; Lee, Sung‐Hyung ; Leung, Irene ; Bonzon, Christine ; Desjarlais, John R. ; Stohl, William ; Szymkowski, David E.</creatorcontrib><description>Objective
Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. The aim of this study was to characterize B cell immunosuppression mediated by the Fc‐engineered antibody, XmAb5871, which coengages FcγRIIb with the B cell antigen receptor (BCR) complex and that is currently in clinical development for the treatment of rheumatoid arthritis (RA). Because rheumatoid factor (RF) might interfere with the binding of XmAb5871 to FcγRIIb, we correlated RF titers with the potency of XmAb5871.
Methods
We analyzed the expression of CD19, FcγRIIb, and CD86 on naive and memory B cells from 50 patients with RA and 66 healthy donors, quantified XmAb5871‐induced promotion of FcγRIIb phosphorylation and suppression of calcium flux in activated B cells, measured CD86 inhibition in whole blood, and correlated RF and anti−citrullinated protein antibody (ACPA) levels with drug potency. We engrafted RA peripheral blood mononuclear cells (PBMCs) into SCID mice, treated them with XmAb5871, and quantified human total IgG, total IgM, and anti‐tetanus IgG antibody levels in vivo.
Results
B cells from all donors expressed CD19 and FcγRIIb, and the expression of FcγRIIb was higher on naive, but not memory, B cells from donors with RA compared with healthy donors. BCR‐mediated calcium flux was suppressed by XmAb5871 and was associated with FcγRIIb phosphorylation. XmAb5871 inhibited CD86 induction, and the levels of RF and ACPAs did not affect efficacy. XmAb5871 suppressed B cell activation regardless of disease severity. In SCID mice engrafted with PBMCs from a patient with RA, XmAb5871 suppressed humoral responses.
Conclusion
Coengagement of the BCR complex and FcγRIIb by XmAb5871 inhibits B cell activation and function. The similar potency in patients with RA and healthy donors and the absence of autoantibody interference suggest that XmAb5871 may represent a new therapeutic strategy to suppress autoreactive B cells in RA.</description><identifier>ISSN: 2326-5191</identifier><identifier>EISSN: 2326-5205</identifier><identifier>DOI: 10.1002/art.38334</identifier><identifier>PMID: 24782179</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Antibodies, Anti-Idiotypic - metabolism ; Antibodies, Anti-Idiotypic - pharmacology ; Antigens, CD19 - immunology ; Antigens, CD19 - metabolism ; Arthritis, Rheumatoid - metabolism ; Arthritis, Rheumatoid - pathology ; B-Lymphocytes - drug effects ; B-Lymphocytes - metabolism ; B-Lymphocytes - pathology ; B7-2 Antigen - metabolism ; C-Reactive Protein - metabolism ; Case-Control Studies ; Female ; Heterografts ; Humans ; Leukocytes, Mononuclear - pathology ; Mice ; Mice, SCID ; Peptides, Cyclic - immunology ; Receptors, Antigen, B-Cell - drug effects ; Receptors, Antigen, B-Cell - metabolism ; Receptors, IgG - drug effects ; Receptors, IgG - metabolism</subject><ispartof>Arthritis & rheumatology (Hoboken, N.J.), 2014-05, Vol.66 (5), p.1153-1164</ispartof><rights>Copyright © 2014 by the American College of Rheumatology</rights><rights>Copyright © 2014 by the American College of Rheumatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3254-d1aab59d0d0de1d7051b0042ae97aa7f55cbca5e7095f74795f7f309aa60f2173</citedby><cites>FETCH-LOGICAL-c3254-d1aab59d0d0de1d7051b0042ae97aa7f55cbca5e7095f74795f7f309aa60f2173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.38334$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.38334$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24782179$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chu, Seung Y.</creatorcontrib><creatorcontrib>Yeter, Karen</creatorcontrib><creatorcontrib>Kotha, Roshan</creatorcontrib><creatorcontrib>Pong, Erik</creatorcontrib><creatorcontrib>Miranda, Yvonne</creatorcontrib><creatorcontrib>Phung, Sheryl</creatorcontrib><creatorcontrib>Chen, Hsing</creatorcontrib><creatorcontrib>Lee, Sung‐Hyung</creatorcontrib><creatorcontrib>Leung, Irene</creatorcontrib><creatorcontrib>Bonzon, Christine</creatorcontrib><creatorcontrib>Desjarlais, John R.</creatorcontrib><creatorcontrib>Stohl, William</creatorcontrib><creatorcontrib>Szymkowski, David E.</creatorcontrib><title>Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor</title><title>Arthritis & rheumatology (Hoboken, N.J.)</title><addtitle>Arthritis Rheumatol</addtitle><description>Objective
Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. The aim of this study was to characterize B cell immunosuppression mediated by the Fc‐engineered antibody, XmAb5871, which coengages FcγRIIb with the B cell antigen receptor (BCR) complex and that is currently in clinical development for the treatment of rheumatoid arthritis (RA). Because rheumatoid factor (RF) might interfere with the binding of XmAb5871 to FcγRIIb, we correlated RF titers with the potency of XmAb5871.
Methods
We analyzed the expression of CD19, FcγRIIb, and CD86 on naive and memory B cells from 50 patients with RA and 66 healthy donors, quantified XmAb5871‐induced promotion of FcγRIIb phosphorylation and suppression of calcium flux in activated B cells, measured CD86 inhibition in whole blood, and correlated RF and anti−citrullinated protein antibody (ACPA) levels with drug potency. We engrafted RA peripheral blood mononuclear cells (PBMCs) into SCID mice, treated them with XmAb5871, and quantified human total IgG, total IgM, and anti‐tetanus IgG antibody levels in vivo.
Results
B cells from all donors expressed CD19 and FcγRIIb, and the expression of FcγRIIb was higher on naive, but not memory, B cells from donors with RA compared with healthy donors. BCR‐mediated calcium flux was suppressed by XmAb5871 and was associated with FcγRIIb phosphorylation. XmAb5871 inhibited CD86 induction, and the levels of RF and ACPAs did not affect efficacy. XmAb5871 suppressed B cell activation regardless of disease severity. In SCID mice engrafted with PBMCs from a patient with RA, XmAb5871 suppressed humoral responses.
Conclusion
Coengagement of the BCR complex and FcγRIIb by XmAb5871 inhibits B cell activation and function. The similar potency in patients with RA and healthy donors and the absence of autoantibody interference suggest that XmAb5871 may represent a new therapeutic strategy to suppress autoreactive B cells in RA.</description><subject>Animals</subject><subject>Antibodies, Anti-Idiotypic - metabolism</subject><subject>Antibodies, Anti-Idiotypic - pharmacology</subject><subject>Antigens, CD19 - immunology</subject><subject>Antigens, CD19 - metabolism</subject><subject>Arthritis, Rheumatoid - metabolism</subject><subject>Arthritis, Rheumatoid - pathology</subject><subject>B-Lymphocytes - drug effects</subject><subject>B-Lymphocytes - metabolism</subject><subject>B-Lymphocytes - pathology</subject><subject>B7-2 Antigen - metabolism</subject><subject>C-Reactive Protein - metabolism</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Heterografts</subject><subject>Humans</subject><subject>Leukocytes, Mononuclear - pathology</subject><subject>Mice</subject><subject>Mice, SCID</subject><subject>Peptides, Cyclic - immunology</subject><subject>Receptors, Antigen, B-Cell - drug effects</subject><subject>Receptors, Antigen, B-Cell - metabolism</subject><subject>Receptors, IgG - drug effects</subject><subject>Receptors, IgG - metabolism</subject><issn>2326-5191</issn><issn>2326-5205</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFOwzAQRS0EAgQsuADyEiRK7SSum2UIFCpVQipFYhfZyaQ1SuJgJ4LsOALXYM09OAQnwbQUVngke-x5_tLMR-iQkjNKiNcXpjnzh74fbKBdz_cGPeYRtrnOaUh30IG1D8StkJMBYdtoxwv40KM83EVvt21dG7BW6QrrHE8X0Jai0SrDkWkWRjXK4nMcQ1FYLDt8X0aSDTk9xaLCUdWoz5fX-IKGy1zqrMOzhWhwrKGaizms_y7Lc6jwFFKoG20cUdYFPDuZDI_Sj_e_yngs8bhaKKncrft930dbuSgsHPyce-hudDmLr3uTm6txHE16qe-xoJdRISQLM-ICaMYJo5KQwBMQciF4zlgqU8GAk5DlPODfe-6TUIgByd1M_D10vNKtjX5swTZJqWzqehAV6NYm1M3XD9iQEoeerNDUaGsN5EltVClMl1CSfJuTOHOSpTmOPfqRbWUJ2S-5tsIB_RXwpAro_ldKoulsJfkFNhCaGg</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>Chu, Seung Y.</creator><creator>Yeter, Karen</creator><creator>Kotha, Roshan</creator><creator>Pong, Erik</creator><creator>Miranda, Yvonne</creator><creator>Phung, Sheryl</creator><creator>Chen, Hsing</creator><creator>Lee, Sung‐Hyung</creator><creator>Leung, Irene</creator><creator>Bonzon, Christine</creator><creator>Desjarlais, John R.</creator><creator>Stohl, William</creator><creator>Szymkowski, David E.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201405</creationdate><title>Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor</title><author>Chu, Seung Y. ; Yeter, Karen ; Kotha, Roshan ; Pong, Erik ; Miranda, Yvonne ; Phung, Sheryl ; Chen, Hsing ; Lee, Sung‐Hyung ; Leung, Irene ; Bonzon, Christine ; Desjarlais, John R. ; Stohl, William ; Szymkowski, David E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3254-d1aab59d0d0de1d7051b0042ae97aa7f55cbca5e7095f74795f7f309aa60f2173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Antibodies, Anti-Idiotypic - metabolism</topic><topic>Antibodies, Anti-Idiotypic - pharmacology</topic><topic>Antigens, CD19 - immunology</topic><topic>Antigens, CD19 - metabolism</topic><topic>Arthritis, Rheumatoid - metabolism</topic><topic>Arthritis, Rheumatoid - pathology</topic><topic>B-Lymphocytes - drug effects</topic><topic>B-Lymphocytes - metabolism</topic><topic>B-Lymphocytes - pathology</topic><topic>B7-2 Antigen - metabolism</topic><topic>C-Reactive Protein - metabolism</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Heterografts</topic><topic>Humans</topic><topic>Leukocytes, Mononuclear - pathology</topic><topic>Mice</topic><topic>Mice, SCID</topic><topic>Peptides, Cyclic - immunology</topic><topic>Receptors, Antigen, B-Cell - drug effects</topic><topic>Receptors, Antigen, B-Cell - metabolism</topic><topic>Receptors, IgG - drug effects</topic><topic>Receptors, IgG - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chu, Seung Y.</creatorcontrib><creatorcontrib>Yeter, Karen</creatorcontrib><creatorcontrib>Kotha, Roshan</creatorcontrib><creatorcontrib>Pong, Erik</creatorcontrib><creatorcontrib>Miranda, Yvonne</creatorcontrib><creatorcontrib>Phung, Sheryl</creatorcontrib><creatorcontrib>Chen, Hsing</creatorcontrib><creatorcontrib>Lee, Sung‐Hyung</creatorcontrib><creatorcontrib>Leung, Irene</creatorcontrib><creatorcontrib>Bonzon, Christine</creatorcontrib><creatorcontrib>Desjarlais, John R.</creatorcontrib><creatorcontrib>Stohl, William</creatorcontrib><creatorcontrib>Szymkowski, David E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chu, Seung Y.</au><au>Yeter, Karen</au><au>Kotha, Roshan</au><au>Pong, Erik</au><au>Miranda, Yvonne</au><au>Phung, Sheryl</au><au>Chen, Hsing</au><au>Lee, Sung‐Hyung</au><au>Leung, Irene</au><au>Bonzon, Christine</au><au>Desjarlais, John R.</au><au>Stohl, William</au><au>Szymkowski, David E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor</atitle><jtitle>Arthritis & rheumatology (Hoboken, N.J.)</jtitle><addtitle>Arthritis Rheumatol</addtitle><date>2014-05</date><risdate>2014</risdate><volume>66</volume><issue>5</issue><spage>1153</spage><epage>1164</epage><pages>1153-1164</pages><issn>2326-5191</issn><eissn>2326-5205</eissn><abstract>Objective
Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. The aim of this study was to characterize B cell immunosuppression mediated by the Fc‐engineered antibody, XmAb5871, which coengages FcγRIIb with the B cell antigen receptor (BCR) complex and that is currently in clinical development for the treatment of rheumatoid arthritis (RA). Because rheumatoid factor (RF) might interfere with the binding of XmAb5871 to FcγRIIb, we correlated RF titers with the potency of XmAb5871.
Methods
We analyzed the expression of CD19, FcγRIIb, and CD86 on naive and memory B cells from 50 patients with RA and 66 healthy donors, quantified XmAb5871‐induced promotion of FcγRIIb phosphorylation and suppression of calcium flux in activated B cells, measured CD86 inhibition in whole blood, and correlated RF and anti−citrullinated protein antibody (ACPA) levels with drug potency. We engrafted RA peripheral blood mononuclear cells (PBMCs) into SCID mice, treated them with XmAb5871, and quantified human total IgG, total IgM, and anti‐tetanus IgG antibody levels in vivo.
Results
B cells from all donors expressed CD19 and FcγRIIb, and the expression of FcγRIIb was higher on naive, but not memory, B cells from donors with RA compared with healthy donors. BCR‐mediated calcium flux was suppressed by XmAb5871 and was associated with FcγRIIb phosphorylation. XmAb5871 inhibited CD86 induction, and the levels of RF and ACPAs did not affect efficacy. XmAb5871 suppressed B cell activation regardless of disease severity. In SCID mice engrafted with PBMCs from a patient with RA, XmAb5871 suppressed humoral responses.
Conclusion
Coengagement of the BCR complex and FcγRIIb by XmAb5871 inhibits B cell activation and function. The similar potency in patients with RA and healthy donors and the absence of autoantibody interference suggest that XmAb5871 may represent a new therapeutic strategy to suppress autoreactive B cells in RA.</abstract><cop>United States</cop><pmid>24782179</pmid><doi>10.1002/art.38334</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2326-5191 |
| ispartof | Arthritis & rheumatology (Hoboken, N.J.), 2014-05, Vol.66 (5), p.1153-1164 |
| issn | 2326-5191 2326-5205 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1520345810 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Animals Antibodies, Anti-Idiotypic - metabolism Antibodies, Anti-Idiotypic - pharmacology Antigens, CD19 - immunology Antigens, CD19 - metabolism Arthritis, Rheumatoid - metabolism Arthritis, Rheumatoid - pathology B-Lymphocytes - drug effects B-Lymphocytes - metabolism B-Lymphocytes - pathology B7-2 Antigen - metabolism C-Reactive Protein - metabolism Case-Control Studies Female Heterografts Humans Leukocytes, Mononuclear - pathology Mice Mice, SCID Peptides, Cyclic - immunology Receptors, Antigen, B-Cell - drug effects Receptors, Antigen, B-Cell - metabolism Receptors, IgG - drug effects Receptors, IgG - metabolism |
| title | Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T07%3A21%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Suppression%20of%20Rheumatoid%20Arthritis%20B%20Cells%20by%20XmAb5871,%20an%20Anti%E2%80%90CD19%20Antibody%20That%20Coengages%20B%20Cell%20Antigen%20Receptor%20Complex%20and%20Fc%CE%B3%20Receptor%20IIb%20Inhibitory%20Receptor&rft.jtitle=Arthritis%20&%20rheumatology%20(Hoboken,%20N.J.)&rft.au=Chu,%20Seung%20Y.&rft.date=2014-05&rft.volume=66&rft.issue=5&rft.spage=1153&rft.epage=1164&rft.pages=1153-1164&rft.issn=2326-5191&rft.eissn=2326-5205&rft_id=info:doi/10.1002/art.38334&rft_dat=%3Cproquest_cross%3E1520345810%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1520345810&rft_id=info:pmid/24782179&rfr_iscdi=true |